MUFG Securities EMEA plc Acquires 124,334 Shares of Pfizer Inc. $PFE

MUFG Securities EMEA plc increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 114.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 233,159 shares of the biopharmaceutical company’s stock after purchasing an additional 124,334 shares during the quarter. MUFG Securities EMEA plc’s holdings in Pfizer were worth $5,806,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Edgemoor Investment Advisors Inc. raised its stake in shares of Pfizer by 5.3% during the fourth quarter. Edgemoor Investment Advisors Inc. now owns 267,930 shares of the biopharmaceutical company’s stock worth $6,671,000 after buying an additional 13,529 shares during the last quarter. Impact Partnership Wealth LLC grew its holdings in Pfizer by 28.4% during the fourth quarter. Impact Partnership Wealth LLC now owns 30,822 shares of the biopharmaceutical company’s stock valued at $767,000 after purchasing an additional 6,823 shares during the period. Patrick Mauro Investment Advisor INC. grew its holdings in Pfizer by 0.8% during the fourth quarter. Patrick Mauro Investment Advisor INC. now owns 479,601 shares of the biopharmaceutical company’s stock valued at $11,942,000 after purchasing an additional 3,971 shares during the period. Norges Bank acquired a new position in Pfizer during the fourth quarter valued at approximately $1,830,986,000. Finally, Amica Mutual Insurance Co. grew its holdings in Pfizer by 29.1% during the fourth quarter. Amica Mutual Insurance Co. now owns 202,765 shares of the biopharmaceutical company’s stock valued at $5,048,000 after purchasing an additional 45,701 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Royal Bank Of Canada restated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. Citigroup boosted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Finally, BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Up 0.0%

Pfizer stock opened at $26.18 on Monday. The stock has a market capitalization of $149.23 billion, a PE ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.06 and a twelve month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $26.77 and a 200-day moving average of $26.29.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.